A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

References

• CaporaliRPallaviciniFBFilippiniMTreatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisalAutoimmun Rev200983 274 28019017546
   PubMed Web of Science ®Google Scholar
• SieperJPoddubnyyDNew evidence on the management of spondyloarthritisNat Rev Rheumatol2016125 282 29527052489
   PubMed Web of Science ®Google Scholar
• KlotzUTemlASchwabMClinical pharmacokinetics and use of infliximabClin Pharmacokinet2007468 645 66017655372
   PubMed Web of Science ®Google Scholar
• NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis2014733 516 52824399231
   PubMed Web of Science ®Google Scholar
• MaxwellLJZochlingJBoonenASinghJAVerasMMTanjong GhogomuETNF-alpha inhibitors for ankylosing spondylitisCochrane Database Syst Rev2015 CD00546825887212
   PubMed Web of Science ®Google Scholar
• AshZGaujoux-VialaCGossecLA systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritisAnn Rheum Dis2012713 319 32621803753
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis2014733 492 50924161836
   PubMed Web of Science ®Google Scholar
• SinghJASaagKGBridgesSLJr2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis Rheumatol2016681 1 26
   PubMed Web of Science ®Google Scholar
• BraunJvan den BergRBaraliakosX2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitisAnn Rheum Dis2011706 896 90421540199
   PubMed Web of Science ®Google Scholar
• WardMMDeodharAAklEAAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis Rheumatol2016682 282 29826401991
   PubMed Web of Science ®Google Scholar
• CoatesLCKavanaughAMeasePJGroup for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritisArthritis Rheumatol2016685 1060 107126749174
   PubMed Web of Science ®Google Scholar
• GossecLSmolenJSRamiroSEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 updateAnn Rheum Dis2016753 499 51026644232
   PubMed Web of Science ®Google Scholar
• LapadulaGFerraccioliGFBiosimilars in rheumatology: pharmacological and pharmacoeconomic issuesClin Exp Rheumatol2012304 Suppl 73 S102 S10623078880
   PubMed Web of Science ®Google Scholar
• DranitsarisGAmirEDorwardKBiosimilars of biological drug therapies: regulatory, clinical and commercial considerationsDrugs20117112 1527 153621861538
   PubMed Web of Science ®Google Scholar
• GoelNChanceKBiosimilars in rheumatology: understanding the rigor of their developmentRheumatology (Oxford)2017562 187 19727241704
   PubMed Web of Science ®Google Scholar
• World Health OrganizationWHO Expert Committee on Biological Standardization. Sixty-fifth reportWorld Health Organ Tech Rep Ser2015993 1 262
   Google Scholar
• CrommelinDJAShahVPKlebovichIThe similarity question for biologicals and non-biological complex drugsEur J Pharm Sci201576 10 1725912826
   PubMed Web of Science ®Google Scholar
• DörnerTKayJBiosimilars in rheumatology: current perspectives and lessons learntNat Rev Rheumatol20151112 713 72426282080
   PubMed Web of Science ®Google Scholar
• AltenRCronsteinBNClinical trial development for biosimilarsSemin Arthritis Rheum201544Suppl 6 S2 S826058550
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]Guideline on similar biological medicinal products2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768Accessed June 14, 2017
   Google Scholar
• Food and Drug AdministrationBiosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry2009 Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdfAccessed June 14, 2017
   Google Scholar
• GulacsiLBrodszkyVBajiPBiosimilars for the management of rheumatoid arthritis: economic considerationsExpert Rev Clin Immunol201511Suppl 1 S43 S5226395836
   PubMed Web of Science ®Google Scholar
• JhaAUptonADunlopWCNAkehurstRThe budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European CountriesAdv Ther2015328 742 75626343027
   PubMed Web of Science ®Google Scholar
• ScheinbergMAKayJThe advent of biosimilar therapies in rheumatology – “O brave new world”Nat Rev Rheumatol201287 430 43622664834
   PubMed Web of Science ®Google Scholar
• RogerSDMikhailABiosimilars: opportunity or cause for concern?J Pharm Pharm Sci2007103 405 41017727803
   PubMed Web of Science ®Google Scholar
• ParkWHrycajPJekaSA randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnn Rheum Dis20137210 1605 161223687259
   PubMed Web of Science ®Google Scholar
• YooDHHrycajPMirandaPA randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnn Rheum Dis20137210 1613 162023687260
   PubMed Web of Science ®Google Scholar
• ChoeJ-YProdanovicNNiebrzydowskiJA randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyAnn Rheum Dis2017761 58 6426318384
   PubMed Web of Science ®Google Scholar
• LambertJWyandMLassenCBioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximabInt J Clin Pharmacol Ther2016544 315 32226952037
   PubMed Web of Science ®Google Scholar
• DerziMJohnsonTRShoiebAMNonclinical Evaluation of PF-0,64,38,179: A Potential Biosimilar to Remicade(®) (Infliximab)Adv Ther20163311 1964 198227585978
   PubMed Web of Science ®Google Scholar
• KaurPChowVZhangNKrishnanEPharmacokinetic similarity of ABP 710 relative to infliximab: results from a randomized, single-blind, single-dose, parallel group study in healthy subjectsArthritis Rheumatol201668Suppl 10 Available from: http://acrabstracts.org/abstract/pharmacokinetic-similarity-of-abp-710-relative-to-infliximab-results-from-a-randomized-single-blind-single-dose-parallel-group-study-in-healthy-subjects/Accessed May 31, 2017
   Google Scholar
• ParkWYooDHJaworskiJComparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS studyArthritis Res Ther2016181 2526795209
   PubMed Web of Science ®Google Scholar
• YooDHSuhCHShimSCA multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritisAnn Rheum Dis201776 566 57027624791
   PubMed Web of Science ®Google Scholar
• DolinarROReillyMSBiosimilars naming, label transparency and authority of choice – survey findings among European physiciansG B I J201432 58 62
   Google Scholar
• DaneseSFiorinoGMichettiPViewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis OrganizationJournal Crohn’s Colitis2014811 1548 1550
   PubMed Web of Science ®Google Scholar
• Castañeda-HernándezGGonzález-RamírezRKayJScheinbergMABiosimilars in rheumatology: what the clinician should knowRMD Open201511 e00001026509046
   PubMed Web of Science ®Google Scholar
• NjueCStatistical considerations for confirmatory clinical trials for similar biotherapeutic productsBiologicals2011395 266 26921807534
   PubMed Web of Science ®Google Scholar
• KayJSmolenJSBiosimilars to treat inflammatory arthritis: the challenge of proving identityAnn Rheum Dis20137210 1589 159323897773
   PubMed Web of Science ®Google Scholar
• YooDHRacewiczABrzezickiJA phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA studyArthritis Res Ther2016181 8227038608
   PubMed Web of Science ®Google Scholar
• TakeuchiTYamanakaHTanakaYEvaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritisMod Rheumatol2015256 817 82425736355
   PubMed Web of Science ®Google Scholar
• DeclerckPJBiosimilar monoclonal antibodies: a science-based regulatory challengeExpert Opin Biol Ther2013132 153 15623286777
   PubMed Web of Science ®Google Scholar
• VincentFBMorandEFMurphyKMackayFMarietteXMarcelliCAntidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspectiveAnn Rheum Dis2013722 165 17823178294
   PubMed Web of Science ®Google Scholar
• SchaeverbekeTTruchetetMEKostineMBarnetcheTBannwarthBRichezCImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceRheumatology (Oxford)2016552 210 22026268816
   PubMed Web of Science ®Google Scholar
• ThomasSSBorazanNBarrosoNComparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysisBioDrugs2015294 241 25826280210
   PubMed Web of Science ®Google Scholar
• BiggioggeroMDanovaMGenoveseUThe challenging definition of naïve patient for biological drug useAutoimmun Rev2015146 543 54625644102
   PubMed Web of Science ®Google Scholar
• van SchouwenburgPAvan de StadtLAde JongRNAdalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisationAnn Rheum Dis2013721 104 10922759910
   PubMed Web of Science ®Google Scholar
• AardenLARuulsSRWolbinkGImmunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurementCurr Opin Immunol2008204 431 43518619538
   PubMed Web of Science ®Google Scholar
• Emi AikawaNde CarvalhoJFArtur Almeida SilvaCBonfáEImmunogenicity of anti-TNF-alpha agents in autoimmune diseasesClin Rev Allergy Immunol2010382–3 82 8919565360
   PubMed Web of Science ®Google Scholar
• KrintelSBGrunertVPHetlandMLThe frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failureRheumatology (Oxford)2013527 1245 125323459699
   PubMed Web of Science ®Google Scholar
• PradeuTJaegerSVivierEThe speed of change: towards a discontinuity theory of immunity?Nature Publishing Group20131310 764 769
   Google Scholar
• WoodlandDLJump-starting the immune system: prime-boosting comes of ageTrends Immunol2004252 98 10415102369
   PubMed Web of Science ®Google Scholar
• CastiglioneFMantileFDe BerardinisPPriscoAHow the interval between prime and boost injection affects the immune response in a computational model of the immune systemComput Math Methods Med20122012 84232922997539
   PubMed Web of Science ®Google Scholar
• ParkWYooDHMirandaPEfficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension studyAnn Rheum Dis2017762 346 35427117698
   PubMed Web of Science ®Google Scholar
• Ruiz-ArgüelloMBMagureguiARuiz Del AguaAAntibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilarsAnn Rheum Dis2016759 1693 169626965981
   PubMed Web of Science ®Google Scholar
• OlechEBiosimilars: rationale and current regulatory landscapeSemin Arthritis Rheum201645Suppl 5 S1 S10
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationConsiderations in Demonstrating Interchangeability with a Reference Product Guidance for Industry2017 Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm537135.pdfAccessed June 14, 2017
   Google Scholar
• BraunJDeodharADijkmansBEfficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year periodArthritis Rheum2008599 1270 127818759257
   PubMed Web of Science ®Google Scholar
• NikiphorouEKautiainenHHannonenPClinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational dataExpert Opin Biol Ther20151512 1677 168326549204
   PubMed Web of Science ®Google Scholar
• GentileschiSBarrecaCBellisaiFSwitch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseasesExpert Opin Biol Ther20161610 1311 131227266338
   PubMed Web of Science ®Google Scholar
• BenucciMGobbiFLBandinelliFSafety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational studyImmunol Res2017651 419 42227449503
   PubMed Web of Science ®Google Scholar
• Løvik GollGOlsenICJorgensenKKBiosimilar Infliximab (CT-13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway [abstract]Arthritis Rheumatol201668Suppl 10 Available from: http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/Accessed May 31, 2017
   Google Scholar
• GlintborgBSørensenIJJensenDVA Nationwide Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis. Eleven Months’ Clinical Outcomes from the Danbio Registry [abstract]Arthritis Rheumatol201668Suppl 10 Available from: http://acrabstracts.org/abstract/a-nationwide-non-medical-switch-from-originator-to-biosimilar-infliximab-in-patients-with-inflammatory-arthritis-eleven-months-clinical-outcomes-from-the-danbio-registry/Accessed May 31, 2017
   Google Scholar
• GlintborgBKringelbachTMHøgdallENon-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis – impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry [abstract]Arthritis Rheumatol201668Suppl 10 Available from: http://acrabstracts.org/abstract/non-medical-switch-from-originator-to-biosimilar-infliximab-in-patients-with-inflammatory-arthritis-impact-on-s-infliximab-and-antidrug-antibodies-results-from-the-danish-rheumatologic-biobank-and/Accessed May 31, 2017
   Google Scholar
• European Medicines AgencyGuideline on Similar Biological Medicinal Products2005 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdfAccessed June 14, 2017
   Google Scholar
• RoviraJEspinJGarciaLOlryAThe impact of biosimilars’ entry in the EU market [Internet]2011 [cited January 10, 2017]. Available from: http://ec.europa.eu/DocsRoom/documents/7651/attachments/1/translations/en/renditions/pdfAccessed June 14, 2017
   Google Scholar
• Italian Society of RheumatologyItalian Society of Rheumatology position paper on biosimilar [Internet]2015 [cited January 10, 2017]. Available from: http://www.reumatologia.it/obj/files/Biosimiliari/BIOSIMILARI2015.pdf
   Google Scholar
• Netherlands Medicines Evaluation BoardClarification of stance on biological and biosimilar medicines [Internet]2015 [cited January 10, 2017]. Available from: http://english.cbg-meb.nl/latest/news/2015/08/17/clarification-of-stance-on-biological-and-biosimilar-medicinesAccessed June 14, 2017
   Google Scholar